Using gross national product to calculate acceptable immunisation costs: deploying cost-effectiveness calculations in reverse

Pharmacoeconomics. 2003;21(7):497-9. doi: 10.2165/00019053-200321070-00004.
No abstract available

MeSH terms

  • Carcinoma, Hepatocellular / etiology
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / prevention & control
  • Cost-Benefit Analysis
  • Health Care Costs
  • Hepatitis B / complications
  • Hepatitis B / economics*
  • Hepatitis B / prevention & control
  • Hepatitis B Vaccines / economics*
  • Humans
  • Immunization Programs / economics*
  • India / epidemiology
  • Vaccination / economics*

Substances

  • Hepatitis B Vaccines